Home › BELRISE › Filing
🔔 Get instant alerts when BELRISE files quarterly results on BSE Start free trial →

Outcome of Board Meeting

Filed: 13 Nov 2026, 18:41 IST Exchange: NSE Category: Financial Results — Audited Results
H1FY27 results (unaudited): Standalone: Revenue 43.1bn +20% y-y (36.0bn) PAT 2.73bn +21% y-y (2.25bn) Consolidated: Revenue 52.9bn +15% y-y (46.2bn) PAT 2.88bn +18% y-y (2.45bn) FY26 results (audited): Standalone: Revenue 75.3bn PAT 4.78bn Consolidated: Revenue 95.1bn PAT 4.97bn Dividend: 0.55 per share (record date Sep 30, 2026) Commentary: Board approved a fresh Scheme of Amalgamation of wholly owned subsidiary H-One India Private Limited with Belrise Industries Limited, subject to regulatory approvals.
Source: Original filing PDF — view on exchange portal
⚡ You're reading this after the fact — subscribers got it instantly
ISA
Indian Stock Alerts BOT
🚨 BELRISE — Quarterly Results
Revenue: ₹2,35,800 Cr (+12% YoY)
PAT: ₹19,200 Cr (+17% YoY)
EBITDA margin: 16.8%
Board declared ₹10/share dividend. Jio adds 8M subs.
✓✓ 6:47 PM
🎧
Instant audio summaries2-min AI concall recap delivered with every earnings alert
📊
20-quarter financialsRevenue, PAT, EBITDA, margins — auto-extracted from filings
🔍
Forensic red-flag screenAudit, governance, accruals & RPT flags scored automatically
⚡
Instant Telegram alertsResults, board meetings, insider trades — within minutes

Add BELRISE to your watchlist — all of this, automated.

Sign in with Google
14-day Pro trial · No credit card · Cancel anytime

More on Belrise Industries Limited

Important. The summary above is generated automatically from Belrise Industries Limited's own public regulatory filing under SEBI LODR. Indian Stock Alerts is not a SEBI-registered Research Analyst or Investment Adviser. This page is informational, not investment advice, a recommendation to buy or sell any security, or any opinion about the company's business, governance or financial health. Always read the original filing before acting and consult a registered adviser for investment decisions.